FeesSafety
Pluang+

Ipsen raises 2026 sales forecast after 24.6% revenue growth in first nine months

Company Fundamentals
22 Oct 2026
Na
View Source
Bullish
Ipsen raises 2026 sales forecast after 24.6% revenue growth in first nine months

Ipsen reported a 24.6% revenue increase at constant exchange rates for the first nine months of 2026, driven by strong sales in oncology, rare diseases, and neurosciences. The company raised its full-year sales growth forecast to about 23% and expects an operating margin of around 39%. Ipsen also strengthened its R&D pipeline with acquisitions and advanced-stage drug candidates, aiming for future blockbuster treatments. Legal disputes with Galderma over distribution agreements are ongoing but currently have uncertain financial impact.

Ipsen's strong sales growth and raised forecasts provide context for readers. For those following the health sector, 70 out of 150 US health stocks traded on Pluang rose while 79 fell as of Oct 22, 2026, 12:11 WIB. Notable movers include Bruker Corporation at USD 58.88 with a 5.27% increase and Cronos Group at USD 3.45 with a 5.18% increase.

More News

Nexans chosen as preferred supplier for Mallorca-Menorca power cable project to boost Balearic Islands' grid resilience.

Nexans chosen as preferred supplier for Mallorca-Menorca power cable project to boost Balearic Islands' grid resilience.

Nexans has been selected by Red Eléctrica as the preferred supplier for the Mallorca-Menorca 3 interconnection project, a key infrastructure initiative aimed at strengthening the electricity network's security and resilience in the Balearic Islands. ...

Market News
Bullish
12 minutes ago
Roche posts 7% sales growth in Q3 2026, driven by strong demand for innovative medicines and diagnostics.

Roche posts 7% sales growth in Q3 2026, driven by strong demand for innovative medicines and diagnostics.

Roche reported a 7% sales increase at constant exchange rates in Q3 2026, with a 6% rise for the first nine months, fueled by high demand for key medicines like Xolair, Hemlibra, and Ocrevus. The Pharmaceuticals Division led growth, while Diagnostics...

Company Fundamentals
Bullish
12 minutes ago
Ipsen raises 2026 sales growth forecast to 23% after strong Q3 performance

Ipsen raises 2026 sales growth forecast to 23% after strong Q3 performance

Ipsen reported a 24.6% sales growth at constant exchange rates for the first nine months of 2026, driven by strong performance in Oncology, Rare Disease, and Neuroscience segments. The company upgraded its full-year sales growth guidance to around 23...

Company Fundamentals
Bullish
12 minutes ago
Nexans chosen as preferred supplier for Mallorca-Menorca power interconnection project with Red Eléctrica.

Nexans chosen as preferred supplier for Mallorca-Menorca power interconnection project with Red Eléctrica.

Nexans has been selected by Red Eléctrica as the preferred supplier for the Mallorca-Menorca 3 interconnection project, aimed at enhancing the electricity network's security and resilience in the Balearic Islands. The project includes a six-month eng...

Market News
Bullish
12 minutes ago
Nexans reports 10.1% revenue growth in 9M 2026, confirms 2026 outlook with strong performance in electrification segments.

Nexans reports 10.1% revenue growth in 9M 2026, confirms 2026 outlook with strong performance in electrification segments.

Nexans posted a 10.1% increase in revenue to €4.95 billion for the first nine months of 2026, driven by strong organic growth in its electrification segments PWR-Grid and PWR-Connect. The company successfully integrated Republic Wire in the US and co...

Company Fundamentals
Bullish
12 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App